Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022

Thomas Graier, Wolfgang Salmhofer, Constanze Jonak, Wolfgang Weger, Claudia Zikeli, Barbara Gruber, Paul Sator, Knut Prillinger, Alexander Mlynek, Martina Schütz-Bergmayr, Leo Richter, Gudrun Ratzinger, Christoph Sassmann, Clemens Painsi, Nina Häring, Katharina Wippel-Slupetzky, Hans Skvara, Hannes Trattner, Martin Inzinger, Christina BangertChristina Ellersdorfer, Katharina Falkensteiner, Birgit Sadoghi, Alexandra Gruber-Wackernagel, Angelika Hofer, Franz Legat, Bernhard Lange-Asschenfeldt, Matthias Schmuth, Igor Vujic, Wolfram Hötzenecker, Werner Saxinger, Robert Müllegger, Franz Quehenberger, Peter Wolf

Research output: Journal article (peer-reviewed)Journal article


Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients. Patients and Methods: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches. Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).

Original languageEnglish
Pages (from-to)1513-1523
Number of pages11
JournalJDDG - Journal of the German Society of Dermatology
Issue number12
Early online date31 Oct 2023
Publication statusPublished - Dec 2023


  • Psoriasis
  • biologics
  • psoriasis treatment
  • psoriatic arthritis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022'. Together they form a unique fingerprint.

Cite this